DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01294410 (ClinicalTrials.gov)	March 2011	10/2/2011	Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis	A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Placebo;Drug: Anti-IP-10 Antibody	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	Both	305	Phase 2	United States;Australia;Austria;Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;Poland;South Africa

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01294410
(ClinicalTrials.gov)

March 2011

10/2/2011

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)

Colitis, Ulcerative

Drug: Placebo;Drug: Anti-IP-10 Antibody

Bristol-Myers Squibb

NULL

Completed

18 Years

N/A

Both

305

Phase 2

United States;Australia;Austria;Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;Poland;South Africa